![]() ![]() and Active Biotech AB today announced that data from a 36-week, randomized, double-blind, placebo-controlled Phase IIb study demonstrated that an oral 0.6 mg dose of laquinimod given daily significantly reduced magnetic resonance imaging (MRI) disease activity by 38 percent in RRMS patients and was well tolerated. ![]() LAQUINIMOD, A NOVEL ORAL COMPOUND, SHOWED SIGNIFICANT REDUCTION INÄISEASE ACTIVITY IN PAT Jerusalem, Israel and Lund, Sweden, Teva Pharmaceutical Industries Ltd.
0 Comments
Leave a Reply. |